Original paper
SGLT-2 Inhibitors and Cardiovascular Risk
Volume: 71, Issue: 22, Pages: 2497 - 2506
Published: May 28, 2018
Abstract
Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors (SGLT-2i) had lower rates of death and heart failure (HF). Whether the benefits of SGLT-2i vary based upon the presence of cardiovascular disease (CVD) is unknown. This study sought to determine the association between initiation of SGLT-2i therapy and HF or death in patients with and without CVD. The CVD-REAL (Comparative Effectiveness of Cardiovascular...
Paper Details
Title
SGLT-2 Inhibitors and Cardiovascular Risk
Published Date
May 28, 2018
Volume
71
Issue
22
Pages
2497 - 2506